Recent Finacing
Recent Raise
BridgeBio Oncology Therapeutics develops small-molecule inhibitors that target KRAS and PI3K pathways to treat RAS- and PI3K-driven cancers.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at BridgeBio Oncology Therapeutics.
